<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345589</url>
  </required_header>
  <id_info>
    <org_study_id>PBC-3</org_study_id>
    <nct_id>NCT03345589</nct_id>
  </id_info>
  <brief_title>A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis</brief_title>
  <official_title>A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of 18-22mg/kg/d Ursodeoxycholic in refractory Primary Biliary
      Cholangitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients that achieve biochemical remission of primary biliary cholangitis(PBC)</measure>
    <time_frame>Month 6 during treatment with 13-15mg/kg/d ursodeoxycholic acid or 18-22mg/kg/d ursodeoxycholic acid</time_frame>
    <description>Percent of patients that achieve biochemical remission of primary biliary cholangitis(PBC) in two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase</measure>
    <time_frame>Week 2 and Month 1, 3, 6,9,12</time_frame>
    <description>(ALP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamyltransferase</measure>
    <time_frame>Week 2 and Month 1, 3, 6,9,12</time_frame>
    <description>(GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
    <description>(ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase</measure>
    <time_frame>Week 2 and Month 1, 3, 6, 9,12</time_frame>
    <description>(AST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin</measure>
    <time_frame>Week 2 and Month 1, 3, 6, 9,12</time_frame>
    <description>(TB)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>18-22mg/kg/d Ursodeoxycholic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13-15mg/kg/d Ursodeoxycholic group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18-22mg/kg/d Ursodeoxycholic</intervention_name>
    <description>18-22mg/kg/d Ursodeoxycholic</description>
    <arm_group_label>18-22mg/kg/d Ursodeoxycholic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-15mg/kg/d Ursodeoxycholic</intervention_name>
    <description>13-15mg/kg/d Ursodeoxycholic</description>
    <arm_group_label>13-15mg/kg/d Ursodeoxycholic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with primary biliary cholangitis

          -  Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and
             suboptimal response to Ursodeoxycholic Acid

        Exclusion Criteria:

          -  Autoimmune hepatitis

          -  Primary sclerosing cholangitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Ni, MD</last_name>
    <phone>13281091993</phone>
    <email>545043216@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yang</last_name>
      <phone>+8618980601276</phone>
      <email>yangli_hx@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Li Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ursodeoxycholic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

